Summary
Radioimmunotherapy (RIT) using radiolabeled antibodies or its fragments holds great promise for cancer therapy. However, its clinical potential is often limited by the undesirable radiation exposure to normal organs such as liver, kidney, and bone marrow. It is important to develop new strategies in RIT that enable protection of vital organs from radiation exposure while maintaining therapeutic radiation dose to the cancer. One way to achieve this is to clear radiometal rapidly from the circulation after accumulation of radioimmunoconjugates (RIC) in the tumor. Our strategy is to place a highly efficient and specific cleavable linker between radiometal chelate and the tumor targeting agent. Such linker must be resistant to cleavage by enzymes present in the plasma and tumor. After radiotargeting agents have accumulated in the tumor, a cleaving agent (protease) can be administered to the patient “on demand” to cleave the specific linker, resulting in the release of radiometal from the circulating RIC, in a form that can be cleared rapidly by the kidneys. TNKase®, a serine protease tissue plasminogen activator and thrombolytic agent, which has been approved for clinical use in patient with acute myocardial infarction, was selected as an on-demand cleaving agent in our model. TNKase® specific on-demand cleavable (ODC) linkers were identified through screening random internally quenched fluorescent resonance energy transfer (FRET) “one-bead-one-compound” (OBOC) combinatorial peptide libraries. FRET-OBOC peptide libraries containing l-amino acid(s) in the center of the random linear peptide and d-amino acids flanking both sides of the l-amino acid(s) were used for screening. Peptide beads susceptible to TNKase® but resistant to plasma and tumor-associated protease cleavage were isolated for sequence analysis. The focus of this chapter is on the methods that have been used to identify and characterize ODC linkers and protease-specific substrates.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
DeNardo, G. L. (2005) Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin. Oncol. 32, S27–S35.
Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., and Dicke, K. A. (1996) Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol. 24, 1183–90.
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., and Capizzi, R. L. (2005) Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105, 4576–82.
Kumaresan, P. R., Natarajan, A., Song, A., Wang, X., Liu, R., DeNardo, G., DeNardo, S. J., and Lam, K. S. (2007) Development of Tissue Plasminogen Activator Specific “On Demand Cleavable” (ODC) Linkers for Radioimmunotherapy by Screening One-Bead-One-Compound Combinatorial Peptide Libraries. Bioconjugate chemistry ASAP Article 10.1021/bc0602681 S1043-1802(06)00268-0.
5.Beeson, C., Butrynski, J. E., Hart, M. J., Nourigat, C., Matthews, D. C., Press, O. W., Senter, P. D., and Bernstein, I. D. (2003) Conditionally cleavable radioimmunoconjugates: A novel approach for the release of radioisotopes from radioimmunoconjugates. Bioconjug. Chem. 14, 927–33.
DeNardo, G. L., DeNardo, S. J., Peterson, J. J., Miers, L. A., Lam, K. S., Hartmann-Siantar, C., and Lamborn, K. R. (2003) Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin. Cancer Res. 9, 3865S–3872S.
Kumaresan, P. R. and Lam, K. S. (2006) Screening chemical microarrays: Methods and applications. Mol. Biosyst. 2, 259–70.
Lam, K. S. (1998) Enzyme-linked colorimetric screening of a one-bead one-compound combinatorial library. Methods Mol. Biol. 87, 7–12.
Lam, K. S., Lehman, A. L., Song, A., Doan, N., Enstrom, A. M., Maxwell, J., and Liu, R. (2003) Synthesis and screening of “one-bead one-compound” combinatorial peptide libraries. Methods Enzymol. 369, 298–322.
Liu, R., Marik, J., and Lam, K. S. (2003) Design, synthesis, screening, and decoding of encoded one-bead one-compound peptidomimetic and small molecule combinatorial libraries. Methods Enzymol. 369, 271–87.
Chan, W. C. and White, P. D. In: Fmoc Solid Phase Peptide Synthesis, Chan, W. C. and White, P. D., eds. The Practical Approach Series; Oxford University Press, New York, pp 1–74.
King, D. S., Fields, C. G., and Fields, G. B. (1990) A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Pept. Protein Res. 36, 255–66.
Schmid, J. A. and Sitte, H. H. (2003) Fluorescence resonance energy transfer in the study of cancer pathways. Curr. Opin. Oncol. 15, 55–64.
Kohl, T., Heinze, K. G., Kuhlemann, R., Koltermann, A., and Schwille, P. (2002) A protease assay for two-photon crosscorrelation and FRET analysis based solely on fluorescent proteins. Proc. Natl. Acad. Sci. USA 99, 12161–6.
Martin, S. F., Hattersley, N., Samuel, I. D., Hay, R. T., and Tatham, M. H. (2007) A fluorescence-resonance-energy-transfer-based protease activity assay and its use to monitor paralog-specific small ubiquitin-like modifier processing. Anal. Biochem. 363, 83–90.
Lam, K. S., Lebl, M., and Krchnak, V. (1997) The “one-bead-one-compound” combinatorial library method. Chem. Rev. 97, 411–48.
Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. (1991) A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354, 82–4.
Meldal, M., Svendsen, I., Breddam, K., and Auzanneau, F. I. (1994) Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity. Proc. Natl. Acad. Sci. USA 91, 3314–18.
Cannon, C. P., McCabe, C. H., Gibson, C. M., Ghali, M., Sequeira, R. F., McKendall, G. R., Breed, J., Modi, N. B., Fox, N. L., Tracy, R. P., Love, T. W., and Braunwald, E. (1997) TNK-tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial. Circulation 95, 351–6.
Ding, L., Coombs, G. S., Strandberg, L., Navre, M., Corey, D. R., and Madison, E. L. (1995) Origins of the specificity of tissue-type plasminogen-activator. Proc. Natl. Acad. Sci. USA 92, 7627–31.
Guerra, D. R., Karha, J., and Gibson, C. M. (2003) Safety and efficacy of tenecteplase in acute myocardial infarction. Expert Opin. Pharmacother. 4, 791–8.
Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34, 595–8.
Vojkovsky, T. (1995) Detection of secondary amines on solid phase. Pept. Res. 8, 236–7.
Song, A. M., Wang, X. B., Zhang, J. H., Marik, J., Lebrilla, C. B., and Lam, K. S. (2004) Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. Bioorg. Med. Chem. Lett. 14, 161–5.
Liu, R. W. and Lam, K. S. (2001) Automatic Edman microsequencing of peptides containing multiple unnatural amino acids. Anal. Biochem. 295, 9–16.
King, D. S., Fields, C. G., and Fields, G. B. (1990) A cleavage method which minimizes side reactions following Fmoc solid-phase peptide-synthesis. Int. J. Pept. Protein Res. 36, 255–66.
Greg, H. T. (1995) Bioconjugate Techniques, Academic, San Diego.
Moses, J. E. and Moorhouse, A. D. (2007) The growing applications of click chemistry. Chem. Soc. Rev. 36, 1249–62.
Meldal, M. (2002) The one-bead two-compound assay for solid phase screening of combinatorial libraries. Biopolymers 66, 93–100.
Warnecke, A., Fichtner, I., Sass, G., and Kratz, F. (2007) Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch. Pharm. 340, 389–95.
Potrich, C., Tomazzolli, R., Dalla Serra, M., Anderluh, G., Malovrh, P., Macek, P., Menestrina, G., and Tejuca, M. (2005) Cytotoxic activity of a tumor protease-activated pore-forming toxin. Bioconjug. Chem. 16, 369–76.
Harada, M., Sakakibara, H., Yano, T., Suzuki, T., and Okuno, S. (2000) Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J. Control Release 69, 399–412.
Deguchi, J. O., Aikawa, M., Tung, C. H., Aikawa, E., Kim, D. E., Ntziachristos, V., Weissleder, R., and Libby, P. (2006) Inflammation in atherosclerosis: Visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114, 55–62.
Melancon, M. P., Wang, W., Wang, Y., Shao, R., Ji, X., Gelovani, J. G., and Li, C. (2007) A novel method for imaging in vivo degradation of poly(l-glutamic acid), a biodegradable drug carrier. Pharm. Res. 24, 1217–24.
Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., and Tsien, R. Y. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA 101, 17867–72.
Acknowledgments
The authors would like to thank Ekama Onofiok and Urvashi Bharadwaj for proofreading and funding support from NIH PO1CA047829-15A2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kumaresan, P., Luo, J., Lam, K. (2009). On-Demand Cleavable Linkers for Radioimmunotherapy. In: Bugge, T., Antalis, T. (eds) Proteases and Cancer. Methods in Molecular Biology™, vol 539. Humana Press. https://doi.org/10.1007/978-1-60327-003-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-60327-003-8_11
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-002-1
Online ISBN: 978-1-60327-003-8
eBook Packages: Springer Protocols